Your browser doesn't support javascript.
loading
Diffuse large B-cell lymphoma chemotherapy reveals a combined immunodeficiency syndrome in cartilage hair hypoplasia.
Nguyen, Alexandre; Martin Silva, Nicolas; de Boysson, Hubert; Damaj, Gandhi; Aouba, Achille.
Afiliação
  • Nguyen A; CHU de Caen, Department of Internal Medicine and Clinical Immunology, Caen, France.
  • Martin Silva N; CHU de Caen, Department of Internal Medicine and Clinical Immunology, Caen, France.
  • de Boysson H; CHU de Caen, Department of Internal Medicine and Clinical Immunology, Caen, France.
  • Damaj G; CHU de Caen, Department of Clinical Haematology, Caen, France.
  • Aouba A; CHU de Caen, Department of Internal Medicine and Clinical Immunology, Caen, France.
Swiss Med Wkly ; 148: w14606, 2018.
Article em En | MEDLINE | ID: mdl-29688570
ABSTRACT
Cartilage hair hypoplasia (CHH) is a rare autosomal recessive ribosomopathy characterised by skeletal and integumentary system manifestations. It may also present with varied forms and intensities of haematopoietic and/or immune disorders. We report a 27-year-old female who presented a picture of combined immunodeficiency after receiving an adriamycin-based chemotherapy regimen followed by autologous stem cell transplantation. Her medical history indicated neonatal dwarfism, recurrent ear, nose and throat and respiratory infections, and hypogammaglobulinaemia, which were suggestive of a primary minor B-cell immune deficiency. Taken together, the diagnosis of cartilage hair hypoplasia was suspected and confirmed by means of molecular biological analysis. Here, we discuss the causal relationship and molecular mechanisms existing between both primary immunodeficiency and lymphoma conditions and between chemotherapy cytotoxicity and aggravation of the immune system and associated hematopoietic dysfunction, considering the role of all these components in light of the initially undiagnosed cartilage hair hypoplasia. Finally, this case highlights the importance of screening for primary immunodeficiencies in the setting of a diagnosis of lymphoma and/or dwarfism; moreover, CHH must be distinguished from other causes of small size; its diagnosis and complete check-up must include the molecular characterisation, and its management must be global in collaboration with haematologists, immunologists and internists.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Osteocondrodisplasias / Cartilagem / Linfoma Difuso de Grandes Células B / Síndrome da Imunodeficiência Adquirida / Tratamento Farmacológico / Cabelo / Doença de Hirschsprung / Síndromes de Imunodeficiência Tipo de estudo: Diagnostic_studies Limite: Adult / Female / Humans País/Região como assunto: Europa Idioma: En Revista: Swiss Med Wkly Assunto da revista: MEDICINA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Osteocondrodisplasias / Cartilagem / Linfoma Difuso de Grandes Células B / Síndrome da Imunodeficiência Adquirida / Tratamento Farmacológico / Cabelo / Doença de Hirschsprung / Síndromes de Imunodeficiência Tipo de estudo: Diagnostic_studies Limite: Adult / Female / Humans País/Região como assunto: Europa Idioma: En Revista: Swiss Med Wkly Assunto da revista: MEDICINA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: França
...